Vitamin D Immune Function Randomized Trial: What the Evidence Says

Quick Answer

Vitamin D Immune Function Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• In line with this, low plasma levels of vitamin A prior to ASCT did not impact on GVHD risk among adult patients. [Iversen Per Ole (2026); evidence level 2]
• To our knowledge, previous studies have not assessed in more detail whether plasma retinoids or plasma carotenoids (including pro-vitamin A carotenoids) are associated with GVHD. [Iversen Per Ole (2026); evidence level 2]
• Studies on vitamin D have increased tremendously since the vitamin D receptor VDR has been identified in the whole immune cell population, including macrophages, dendritic cells (DCs), T cells, and B cells. [Shende Sandesh (2026); evidence level 3]
• Vitamin D was historically confined to skeletal biology, primarily associated with calcium-phosphate homeostasis and the prevention of rickets, osteomalacia, and osteoporosis. [Shende Sandesh (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For vitamin D immune function randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Iversen Per Ole (2026). Plasma Levels of Retinoids and Carotenoids in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Given Extracorporeal Photopheresis to Prevent Graft‐Versus‐Host Disease—Analyses From a Randomized Trial. DOI: 10.1002/jha2.70296. PMCID: PMC13170472. PMID: 42137823. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13170472/
• Shende Sandesh (2026). Vitamin D as an Immuno-Endocrine Modulator: Discovering Its Role in Autoimmune Disorders and Host Defense Mechanisms. DOI: 10.3390/jcm15124742. PMCID: PMC13301028. PMID: 42355910. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13301028/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.